Previous Page  24 / 31 Next Page
Information
Show Menu
Previous Page 24 / 31 Next Page
Page Background

CABOSUN: Seguridad

Efectos adversos reportados G1/2 ≥20%

Cabozantinib (n=78)

Sunitinib (n=72)

Adverse event, %

Grade 1/2 Grade 3

Grade 4

Grade 1/2

Grade 3

Grade 4

Any AE

24

58

10

24

58

7

Diarrhoea

b

63

10

0

43

11

0

AST increased

b

58

1

1

28

3

0

Fatigue

b

58

6

0

51

17

0

ALT increased

b

50

4

1

28

0

0

Appetite decreased

42

5

0

31

1

0

Dysgeusia

41

0

0

29

0

0

Hypertension

b

39

28

0

24

19

1

Platelet count decreased

b

38

1

0

50

8

3

PPE syndrome

b

35

8

0

29

4

0

Anaemia

32

1

0

43

3

0

Stomatitis

32

5

0

24

6

0

Nausea

29

3

0

35

4

0

Weight decreased

28

4

0

17

0

0

Dyspepsia

27

0

0

17

0

0

Neutrophil count decreased

b

15

0

0

31

4

0

White blood cell count decreased

12

0

0

32

3

0

Choueiri TK, et al.

J Clin Oncol

2017;35:591–7 ("Errata."

J Clin Oncol,

35(32), p. 3736)